Wyeth execs get big roles in new Pfizer

Pfizer has opened the doors of top management to eight Wyeth execs. After the two companies merge, Wyeth types will serve in leadership roles from R&D to consumer health, with at least two reporting directly to Pfizer CEO Jeff Kindler.

One of those top two is Cavan Redmond, who now heads up Wyeth's consumer healthcare group; he'll be group president of Pfizer Diversified Businesses. The other is Mikael Dolsten (photo), Wyeth's research chief, who will lead Pfizer's new BioTherapeutics Research Group as president.

Ex-Wyethers will be president of specialty care and vaccines (Geno Germano) and president of vaccines (Jim Connolly). Wyeth's consumer healthcare chief, Cavan Redmond, will become group president of Pfizer Diversified Businesses, reporting directly to CEO Jeff Kindler (photo). Heading up consumer health for Pfizer--reporting to Redmond--will be Wyeth's Paul Sturman, and Wyeth's Erica Mann will be president of nutritional health. And two Wyeth research leaders will take over as chief scientific officers in charge of vaccine research and neuroscience research, respectively: Emilio Emini (photo) and Menelas Pangalos (photo).

"By putting together these businesses and combining in one team a number of strong and experienced Pfizer and Wyeth leaders," Kindler said in a statement, "we are creating the world's premier biopharmaceutical company--one that is powerfully positioned to provide substantial value for patients, customers, colleagues and shareholders."

Does the adoption of so many Wyeth managers mean that those farther down the Wyeth org chart might not suffer the lion's share of promised job cuts? Usually, it's the acquired company that loses the most workers in a merger, but In Vivo surmises that the $4 billion in cost savings are likely to be "more fairly distributed" with some Wyeth leaders in on the decision-making. But we'll have to wait to find out for sure.

- see the Pfizer release

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.